 |
Julphar registers its insulin in 17 countriesThe UAE-based pharmaceutical manufacturer Gulf Pharmaceutical Industries (Julphar) recently announced the registration and marketing of Emirates manufactured insulin, in both raw and packaged forms, in 17 countries, said a report. More… |
|
Julphar registers its insulin in 17 countriesThe UAE-based pharmaceutical manufacturer Gulf Pharmaceutical Industries (Julphar) recently announced the registration and marketing of Emirates manufactured insulin, in both raw and packaged forms, in 17 countries, said a report. More… |
 |
Gulf Biotech plans $93m insulin factory in BahrainGulf Biotech Company, a venture backed by Saudi investors, plans to set up a new insulin factory in Bahrain at an investment of $93 million, said a report. The project is being backed by an alliance involving global multinationals More… |
 |
Type 1 diabetes vaccine shows promiseAn early stage study suggests an experimental vaccine may be able to tame bits of the immune system that go haywire in people with type 1 diabetes, offering hope for a new way to delay or prevent the autoimmune disease, researchers said on Wedne More… |
 |
New finding may do away with insulin injectionAustralian scientists have discovered how insulin is taken up by cells, potentially opening the way for new drugs for diabetes patients that can be administered without injection. The team, whos More… |
 |
Bahrain to set up $93m insulin plantBahrain is to set up an insulin production plant at a cost of BD35 million ($93 million) in line with its strategy to supply lifesaving products to people with diabetes across the Gulf region. The Gulf Biotic facility will be constructed o More… |
 |
Infant diabetes ‘rising in Bahrain’The number of babies with diabetes, who require insulin from birth, has tripled in Bahrain in the last 20 years, according to a health expert. Latest figures show that 25 out of 100,000 babies were born with type one insulin dependent Diab More… |
 |
Onglyza reduces blood sugar levels: studyPharmaceutical companies Bristol-Myers Squibb and AstraZeneca have announced results from an investigational phase 3b clinical study of use of Onglyza (saxagliptin) in diabetic patients. The study was based on the addition of Onglyza (saxa More… |
 |
Insulin releasing switch discoveredThe molecular switch for the secretion of insulin — the hormone that regulates blood sugar — has been uncovered, providing for the first time an explanation of this process, said a report. In a report published online recently in Cell Meta More… |
 |
Boehringer, Eli Lilly in major diabetes drugs dealBoehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialise a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two More… |
